Glucotrack, Inc. filed a Current Report on Form 8-K dated September 22, 2026, disclosing amendments to several securities purchase agreements. The company has entered into amendments to Bridge Warrants, Common Warrants, and September Warrants, as well as an amendment to September Notes. The amendments were executed between September 22 and September 28, 2026.
The Bridge Warrant Amendment, Amendment No. 2 to Common Warrant, and September Warrant Amendment all remove provisions that permitted downward adjustments to the Floor Price. The September Note Amendment further modifies the terms by revising anti-dilution adjustment provisions. Under these revisions, the Floor Price functions as an absolute floor below which no conversion may occur and the Conversion Price cannot be reduced. Additionally, the September Note Amendment changes the make-whole payment provision, requiring that any True-Up Amount be satisfied only in cash.
The company previously disclosed these transactions in July and August 2026. On July 14, 2026, Glucotrack entered into a securities purchase agreement with Bridge Investors, issuing senior secured convertible promissory notes and common stock purchase warrants. On August 4, 2026, the company entered into an Interim PIPE SPA with a PIPE Purchaser, issuing pre-funded warrants and common stock purchase warrants. On September 10, 2026, the company entered into a September Purchase Agreement with September Investors, issuing senior secured convertible promissory notes and common stock purchase warrants. The form of these amendments is filed as Exhibits 4.1 through 4.4 to the current report.
